Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors
BackgroundUnderstanding the risk factors for early recurrence is crucial for improving endometrial cancer (EC) patient outcomes.MethodsWe conducted a retrospective analysis of clinicopathological data from 473 patients diagnosed with EC at the First Affiliated Hospital of Chongqing Medical Universit...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1500658/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558741246279680 |
|---|---|
| author | Zhen Huang Xue Li Ling Li |
| author_facet | Zhen Huang Xue Li Ling Li |
| author_sort | Zhen Huang |
| collection | DOAJ |
| description | BackgroundUnderstanding the risk factors for early recurrence is crucial for improving endometrial cancer (EC) patient outcomes.MethodsWe conducted a retrospective analysis of clinicopathological data from 473 patients diagnosed with EC at the First Affiliated Hospital of Chongqing Medical University between October 2013 and May 2019. We evaluated factors influencing early recurrence(defined as occurring within 12 months after treatment) based on 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system.ResultsAmong the 473 patients, 284 (60.1%) were diagnosed with stage I, 117 (24.7%) with stage II, and 72 (15.2%) with stage III. A total of 343 patients (72.5%) had non-aggressive EC, while 130 patients (27.5%) had aggressive EC. Our findings identified higher FIGO stage, lymphovascular space invasion, estrogen receptor negativity, and abnormal P53 expression as significant independent risk factors for early recurrence. Of the 473 patients, 83 (17.6%) experienced recurrence, with 44 patients (53.0%) relapsing within 12 months post-treatment. Patients with early recurrence had significantly worse prognoses compared to those with late recurrence or no recurrence(P < 0.001).ConclusionThe identification of these risk factors is essential for developing individualized treatment plans and postoperative management strategies. Our study highlights the need for targeted therapies and intensified follow-up for high-risk patients to improve outcomes in endometrial cancer. |
| format | Article |
| id | doaj-art-063e3afb4fb54126bc1a5231a95087ed |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-063e3afb4fb54126bc1a5231a95087ed2025-01-06T06:58:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15006581500658Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factorsZhen Huang0Xue Li1Ling Li2Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Ultrasound, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaBackgroundUnderstanding the risk factors for early recurrence is crucial for improving endometrial cancer (EC) patient outcomes.MethodsWe conducted a retrospective analysis of clinicopathological data from 473 patients diagnosed with EC at the First Affiliated Hospital of Chongqing Medical University between October 2013 and May 2019. We evaluated factors influencing early recurrence(defined as occurring within 12 months after treatment) based on 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system.ResultsAmong the 473 patients, 284 (60.1%) were diagnosed with stage I, 117 (24.7%) with stage II, and 72 (15.2%) with stage III. A total of 343 patients (72.5%) had non-aggressive EC, while 130 patients (27.5%) had aggressive EC. Our findings identified higher FIGO stage, lymphovascular space invasion, estrogen receptor negativity, and abnormal P53 expression as significant independent risk factors for early recurrence. Of the 473 patients, 83 (17.6%) experienced recurrence, with 44 patients (53.0%) relapsing within 12 months post-treatment. Patients with early recurrence had significantly worse prognoses compared to those with late recurrence or no recurrence(P < 0.001).ConclusionThe identification of these risk factors is essential for developing individualized treatment plans and postoperative management strategies. Our study highlights the need for targeted therapies and intensified follow-up for high-risk patients to improve outcomes in endometrial cancer.https://www.frontiersin.org/articles/10.3389/fonc.2024.1500658/fullendometrial cancerearly recurrenceLVSIestrogen receptorp53 |
| spellingShingle | Zhen Huang Xue Li Ling Li Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors Frontiers in Oncology endometrial cancer early recurrence LVSI estrogen receptor p53 |
| title | Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors |
| title_full | Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors |
| title_fullStr | Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors |
| title_full_unstemmed | Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors |
| title_short | Early recurrence after surgery in FIGO 2023 stage I-III endometrial cancer: characteristics and risk factors |
| title_sort | early recurrence after surgery in figo 2023 stage i iii endometrial cancer characteristics and risk factors |
| topic | endometrial cancer early recurrence LVSI estrogen receptor p53 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1500658/full |
| work_keys_str_mv | AT zhenhuang earlyrecurrenceaftersurgeryinfigo2023stageiiiiendometrialcancercharacteristicsandriskfactors AT xueli earlyrecurrenceaftersurgeryinfigo2023stageiiiiendometrialcancercharacteristicsandriskfactors AT lingli earlyrecurrenceaftersurgeryinfigo2023stageiiiiendometrialcancercharacteristicsandriskfactors |